Acute Hip Fracture Study in Patients 65 Years or Greater
| Status: | Completed |
|---|---|
| Conditions: | Orthopedic, Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 65 - Any |
| Updated: | 4/17/2018 |
| Start Date: | October 30, 2015 |
| End Date: | March 2018 |
A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture
This is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to
investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.
Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be
eligible for participation 3-7 weeks post-injury.
investigate the safety, tolerability, and efficacy of VK5211 after 12 weeks of treatment.
Males and females ≥65 years old who are ambulatory and recovering from a hip fracture will be
eligible for participation 3-7 weeks post-injury.
Inclusion Criteria:
- Males or females ≥65 years old who are recovering from a hip fracture (occurring 3-7
weeks prior) with no residual surgical issues will be eligible for participation.
Exclusion Criteria:
- Pathological fracture (e.g. fracture due to Paget's disease of bone, malignancy,
etc.). Fracture due to postmenopausal osteoporosis is not considered pathological for
this trial.
We found this trial at
8
sites
Click here to add this to my saved trials
Budapest, 1188
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Madison, Wisconsin 53705
Phone: 608-265-6410
Click here to add this to my saved trials
Click here to add this to my saved trials